Background Pathologic fractures of the femur resulting from metastasis severely increase mortality in patients with nonsmall cell lung cancer (NSCLC). However, factors associated with early mortality after surgery have not been elucidated. Questions/purposes The purpose of this study was to identify clinical and laboratory factors available to surgeons before surgery for a metastatic femur in patients with metastatic lung cancer that might be associated with mortality at 1 and 3 months. Methods Between 2010 and 2014 we treated 126 patients for pathologic fracture of the femur caused by NSCLC. Of those, complete data sets for the parameters of interest (including clinical factors, laboratory factors, and survivorship) were available in 105 (83%). The factors we considered included sex, age, fracture location, surgical procedure, postoperative complications, blood cell counts, serum biomarkers, genetic alterations of primary cancer, chemotherapeutic agents, preoperative radiation therapy, pleural effusion, bone and internal organ metastasis, performance scores, and medical center where the treatment was performed. Multivariate logistic regression was performed to identify factors associated with mortality at 1 and 3 months. Results Intertrochanteric location was associated with a higher risk of death (odds ratio [OR], 17.0; 95% confidence interval [CI], 2.65-109.5), lower serum albumin level was associated with an increased risk of death (OR, 0.13; 95% CI, 0.028-0.60), and availability of a suitable chemotherapeutic target agent was associated with a lower risk of death (OR, 0.28; 95% CI, 0.08-0.91) within 3 months of surgery. Undergoing reconstruction with an endoprosthesis was associated with a higher risk of death (OR, 48.3; 95% CI, 1.7-1329) and elevated serum leukocyte count (OR, 1.2; 95% CI, 1.0-1.4) and elevated alanine aminotransferase (ALT) were associated with a higher risk of death (OR, 1.1; 95% CI, 1.0-1.2) within 1 month of surgery. Conclusions Although the risk factors for early mortality need to be validated by prospective studies, surgical options
Introduction
Nonsmall cell lung cancer (NSCLC) is one of the most common causes of bone metastases after breast and prostate cancer. Approximately 30% to 40% of patients with NSCLC develop bone metastasis during the natural course of the disease [18, 19] . Most patients who have experienced pathologic fractures in long bones have a limited life expectancy with a reported median survival of < 10 months [20] . The proximal femur is the most frequent site of long bone metastases, which severely affects patients' quality of life and increases the mortality rate because of surgeryrelated complications [4, 5, 11, 22] . The treatment strategy should be tailored according to the estimated life expectancy of each patient [1] , and accurate prediction of patients' life expectancy is therefore crucial for planning the appropriate fracture treatment strategy.
Recent studies have attempted to identify prognostic factors that predict postoperative life expectancy by assessing preoperative demographic and functional status in metastatic bone tumors [6, 10, 12, [14] [15] [16] . Because most of these studies included heterogeneous solid tumors, the specific factors affecting survival in patients with NSCLC have not been fully elucidated.
We therefore sought to identify clinical and laboratory factors available to surgeons before surgery of the metastatic femur in patients with NSCLC that might be associated with early mortality at 1 and 3 months after surgery.
Patients and Methods
Between 2010 and 2014 we treated 126 patients for pathologic fracture of the femur caused by NSCLC in the National Cancer Center and Samsung Medical Center. Patients with poor medical records or with < 1-month followup were excluded. Of those, complete data sets for the parameters of interest here (including clinical factors, laboratory factors, and survivorship) were available in 105 (83%) (81 patients from Samsung Medical Center and 24 from the National Cancer Center).
Surgical indications included overt and impending fracture of the femur. Impending fracture was identified according to Mirels' criteria [13] . Surgical contraindications included inoperable general conditions such as sepsis, confused mental state, bedridden state resulting from paraplegia, and other poor medical conditions that led to an estimated life expectancy of < 1 month.
We The mean age of the study population was 62 years (range, 24-83 years; SD 11). There were 60 men and 45 women. Forty-seven were located in the femoral neck area, 16 were in the intertrochanteric area, 15 were in the subtrochanteric area, and 27 were in the femoral shaft area.
Genetic mutations of the tumors were evaluated in 50 cases. Among them the mutation of EGFR was found in 24 cases, K-RAS mutation was found in one case, ALK mutation was found in two cases, and PDL-1 mutation was found in three cases.
Forty-two patients underwent bipolar arthroplasty, 21 underwent tumor-prosthesis surgery, and 34 underwent intramedullary nailing.
During the observation time, 57 patients (56%) died. Ten patients (10%) experienced complications after surgery, which included three postoperative lung complications, three deep infections, and four implant failures. All patients with periprosthetic fracture underwent surgery including osteosynthesis and prosthetic arthroplasty.
Short-term survival or early mortality was evaluated as a primary outcome measure. The risk factors were evaluated at a discrete time point (1 and 3 months after surgery).
Statistical Analysis
We performed multivariate logistic regression analysis of the patients stratified by survival either exceeding or < 1 month and 3 months to identify the risk factors. Initially, candidate variables (p < 0.1 in univariate analysis) were selected among the 40 variables. The selected variables were subjected to multivariate logistic regression and confounding variables were controlled by a stepwise procedure.
The receiver operating characteristic (ROC) curve was generated to evaluate the cutoff point of continuous values. The cutoff value was determined at the point that maximizes the Youden index (sensitivity + specificity-1). Pearson chi square analysis was performed to find confounders among the variables.
Statistical analysis was performed using IBM SPSS Statistics 23 (La Jolla, CA, USA) software. The results are described as mean 6 standard error unless otherwise specified.
Results

Factors Associated With 3-month Mortality
After controlling for relevant confounding variables such as intertrochanteric location, postoperative complications, serum leukocyte count, serum protein, albumin, ALT, creatinine, K-RAS mutation, ALK mutation, chemotherapeutic agents, and institutional difference, we found that intertrochanteric location was associated with an increased risk of death (odds ratio [OR], 17.0; 95% confidence interval [CI], 2.65-109.5; p = 0.003), lower serum albumin level was associated with an increased risk of death (OR, 0.13; 95% CI, 0.028-0.60; p = 0.009), and the availability of a suitable chemotherapeutic target agent was associated with a decreased risk of death (OR, 0.28; 95% CI, 0.08-0.91; p = 0.034) within 3 months of surgery (Table 2) . No other covariate we evaluated was associated with differences in 3-month mortality. Area under the ROC curve (AUC) of serum albumin for differentiating the 3-month mortality group was 0.73 (95% CI, 0.59-0.87). At the cutoff value of 3.6 g/dL, sensitivity was 78.6 % and specificity was 64.4% (Fig. 1A) .
Factors Associated With 1-month Mortality
After controlling for relevant confounding variables such as tumor-prosthesis, postoperative complications, serum leukocyte count, ALT, liver metastasis, and pleural *Normal ranges shown in parentheses. EGFR = epidermal growth factor receptor gene; K-RAS = Kirsten-ras protein oncogene; ALK = anaplastic lymphoma receptor tyrosine kinase gene; PDL-1 = programmed death-ligand 1 gene; WBC = white blood cell count. AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase; BUN = blood urea nitrogen; Ca = calcium; P = phosphorus; ECOG = Eastern Cooperative Oncology Group score.
Volume 476, Number 9 Prognosis of NSCLC Femoral Metastasis 1817 OR = odds ratio; CI = confidence interval; IM = intramedullary; Hb = hemoglobin; AST = aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase; BUN = blood urea nitrogen; Ca = calcium; P = phosphorus; EGFR = epidermal growth factor receptor gene; K-RAS = Kirsten-ras protein oncogene; ALK = anaplastic lymphoma receptor tyrosine kinase gene; PDL-1 = programmed death-ligand 1 gene; ECOG = Eastern Cooperative Oncology Group score; RT = radiation therapy.
effusion, we found that undergoing reconstruction with an endoprosthesis (OR, 48.3; 95% CI,1.7-1329; p = 0.023), elevated serum leukocyte count (OR, 1.2; 95% CI, 1.0-1.4; p = 0.015), and elevated ALT (OR, 1.1; 95% CI, 1.0-1.2; p = 0.038) were associated with 1-month mortality after surgery (Table 3) . AUC of serum leukocyte count for 1-month mortality was 0.83 (95% CI, 0.7-0.96). The cutoff value was 9.87 x 10 9 /L, where sensitivity was 100% and specificity was 70% (Fig. 1B) . AUC of serum ALT for 1-month mortality was 0.67 (95% CI, 0.4-0.9). The cutoff value was 15 U/L, where sensitivity was 80% and specificity was 52% (Fig. 1C) .
Discussion
A substantial proportion of patients with NSCLC will experience bone metastases during the course of their disease [3, 18, 19] . Because patients with NSCLC have a limited life expectancy, it seems important to identify those patients who are likely to survive at least a few months to help guide surgical decision-making with respect to pathologic fractures and impending pathologic fractures so as not to have patients spending their last days or weeks recovering from orthopaedic surgery. Therefore, an accurate estimation of patients' life expectancy is essential for planning the appropriate fracture treatment strategy for each patient.
We note the following limitations. The small sample size might have contributed to a lack of power to resolve potentially important associated variables. Although we evaluated 40 variables, there may have been others that were important but could not be included. In addition, the variables we studied represented potential associations, but we did not demonstrate causation. We believe that larger studies might better be able to evaluate the association between intertrochanteric fracture and other possible risk factors. Because the purpose of the study was to find preoperative factors associated with mortality, we did not include complications of surgery in our multivariate analysis; however, we believe the reason why patients who underwent reconstruction with an endoprosthesis (rather than internal fixation) was associated with 1-month mortality was the fact that endoprosthetic reconstruction is a larger operation that is associated with more complications than internal fixation, and perhaps the occurrence of those complications contributed to deaths within 1 month of surgery.
Several independent factors have been identified as being associated with early mortality of patients with skeletal metastases, which include ECOG score [16] , number of bone metastases, presence of visceral metastasis, serum hemoglobin level [15] , and type of reconstruction procedure [14] . Katagiri et al. [10] proposed new prognostic factors and a new scoring system for patients with skeletal metastasis. Using the Cox proportional hazards model, they identified prognostic factors including primary lesion, visceral metastasis, abnormal laboratory data, performance score, previous chemotherapy, and multiple skeletal involvement, all of which were also considered for the current study. Forsberg et al. [6] developed a new Bayesian belief network to estimate survival in patients undergoing surgery for skeletal metastasis. This decision-supporting tool called PATHFx (www. pathfx.org) estimates survival time with good accuracy. However, those prediction models included heterogeneous solid tumors; the specific factors affecting survival in patients with NSCLC have not been fully elucidated. In the current study, we identified a number of patient-and disease-specific factors that are associated with early death after surgery in patients with NSCLS.
We found that pathologic fractures in the intertrochanteric region are associated with extensive bone loss Fig. 1 A-C ROC curves were generated to evaluate the cutoff value of serum albumin (A), serum leukocyte count (B), and ALT (C). The curve plots show the true-positive rate (sensitivity) against the false-positive rate (1-specificity).
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Prognosis of NSCLC Femoral Metastasis 1819 indicating greater local advancement than that in femoral neck fractures. Therefore, it is perhaps not surprising that patients with intertrochanteric lesions have a poor prognosis. Because surgical options are tailored based on anatomic locations, the outcomes of different anatomic locations may be influenced by surgical procedures. Although we found no association between the surgical procedure chosen and early death, small numbers (insufficient statistical power) limit our confidence in this analysis. Previous studies have shown that serum albumin level may have prognostic value in certain cancer types and different cancer stages and that hypoalbuminemia is associated with a poor prognosis [8] . Tanriverdi et al. found that low serum albumin levels were an independent prognostic factor for NSCLC [21] . The current study suggested the cutoff value should be 3.6, which is a lower margin of the normal range (3.5-5.0 g/dL). Therefore, the preoperative serum albumin level below the lower margin might be considered a risk factor for 3-month mortality.
Targeted agents have been approved for patients with advanced NSCLC with EGFR mutations, ALK translocations, or ROS-1 rearrangements. EGFR-tyrosine kinase inhibitors significantly improved the prognosis of patients with advanced NSCLS with EGFR mutations [7] . Indeed, our patients who were treated with targeted chemotherapy also showed a better prognosis within 3 months after surgery.
The factors associated with 1-month mortality differed from those associated with 3-month mortality. One-month mortality seemed to be related to more critical conditions such as postoperative complications and leukocytosis. Previous work suggests that leukocytosis and thrombocytosis are associated with inferior prognoses in patients with cancer [9] . These two commonly used laboratory markers may be useful for prognosis prediction while considering surgery. Boddu et al. demonstrated that paraneoplastic leukocytosis and paraneoplastic thrombocytosis have prognostic significance in NSCLC [2] . Leukocytosis is defined as total leukocyte counts above 11 3 10 9 /L. We determined the cutoff point as 10 3 10 9 /L with 100% sensitivity and 70% specificity, which is a marginally high level. Therefore, surgical options should be carefully considered for patients who have total leukocyte counts above normal or marginally high on the preoperative laboratory test.
The current study showed that higher ALT levels were associated with early mortality. Elevated ALT levels were often found in a wide range of disorders affecting the liver, heart, skeletal muscles, and kidneys. Okugawa et al. attempted to identify feasible biomarkers for predicting early mortality in patients with terminal cancer. They found that elevated levels of ALT (> 45 U/L), total bilirubin, blood urea nitrogen, and creatinine and a decreased platelet count were significant predictors for early mortality [17] . The cutoff value of 15 U/L was measured by maximizing the Youden index, which yields sensitivity of 80% and specificity of 52%. Because this cutoff level is within the normal range (0-45 IU/L), ALT should be a less useful predictor in the real clinical setting compared with leukocytosis and lower albumin level.
In summary, we found that intertrochanteric fracture location, lower albumin level, and the absence of a target agent were associated with increased 3-month mortality after surgery. We also showed that leukocytosis, high ALT, and reconstruction with an endoprosthesis were associated with death within 1 month of surgery for patients with skeletal metastases from NSCLC. Although the risk factors for early mortality need to be validated by prospective studies, surgical options need to be reconsidered in patients with femoral metastases from NSCLS showing high ALT or leukocytosis in the preoperative blood test.
